Browse the corpus

REFERENCES Bargetzi MJ, Tichelli A, Gratwohl A, et al, "Oral All-transretinoic Acid Administration in Intubated Patients With Acute Promyelocytic Leukemia," Schweiz Med Wochenschr , 1996, 126(45):1944-5. [PubMed 8946598 ] de Botton S, Coiteux V, Chevret S, et al, "Outcome of Childhood Acute Promyelocytic Leukemia With All- Trans -Retinoic Acid and Chemotherapy," J Clin Oncol , 2004, 22(8):1404-12. [PubMed 15084614 ] Gregory J, Kim H, Alonzo T, et al, "Treatment of Children With Acute Promyelocytic Leukemia: Results of the First North American Intergroup Trial INT0129," Pediatr Blood Cancer , 2009, 53(6):1005-10. [PubMed 19743516 ] Kueh YK, Liew PP, Ho PC, et al, "Sublingual Administration of All- Trans -retinoic Acid to a Comatose Patient With Acute Promyelocytic Leukemia," Ann Pharmacother , 1999, 33(4):503-5. [PubMed 10332546 ] Mann G, Reinhardt D, Ritter J, et al, "Treatment With All-trans Retinoic Acid in Acute Promyelocytic Leukemia Reduces Early Deaths in Children," Ann Hematol , 2001, 80(7):417-22. [PubMed 11529468 ] National Comprehensive Cancer Network® (NCCN), “Practice Guidelines in Oncology™: Acute Myeloid Leukemia,” Version 1, 2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf. Ortega JJ, Madero L, Martín G, et al, "Treatment With All- trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group," J Clin Oncol , 2005, 23(30):7632-40. [PubMed 16234524 ] Sanz MA, Grimwade D, Tallman MS, et al, "Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet," Blood , 2009, 113(9):1875-91. [PubMed 18812465 ] Sanz MA, Martín G, González M, et al, "Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All- trans -retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group," Blood , 2004, 103(4):1237-43. [PubMed 14576047 ] Sanz MA, Montesinos P, Vellenga E, et al, "Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All- trans Retinoic Acid and Anthracycline Monochemotherapy: Long-Term Outcome of the LPA 99 Multicenter Study by the PETHEMA Group," Blood , 2008, 112(8):3130-4. [PubMed 18664623 ] Shaw PJ, Atkins MC, Nath CE, et al, "ATRA Administration in the Critically Ill Patient," Leukemia , 1995, 9(7):1288. [PubMed 7630206 ]

Sanz MA, Montesinos P, Vellenga E, et al, "Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All- trans Retinoic Acid and Anthracycline Monochemotherapy: Long-Term Outcome of the LPA 99 Multicenter Study by the PETHEMA Group," Blood , 2008, 112(8):3130-4. [PubMed 18664623 ] Shaw PJ, Atkins MC, Nath CE, et al, "ATRA Administration in the Critically Ill Patient," Leukemia , 1995, 9(7):1288. [PubMed 7630206 ] Takitani K, Koh M, Inoue A, et al, "Pharmacokinetics of All- Trans Retinoic Acid in Adults and Children With Acute Promyelocytic Leukemia," Am J Hematol , 2006, 81(9):720-1. [PubMed 16838336 ] Takitani K, Nakao Y, Kosaka Y, et al, "Low Plasma Level of All- trans Retinoic Acid After Feeding Tube Administration for Acute Promyelocytic Leukemia," Am J Hematol , 2004, 76(1):97-8. [PubMed 15114613 ] Testi AM, Biondi A, Lo Coco F, et al, "GIMEMA-AIEOPAIDA Protocol for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in Children," Blood , 2005, 106(2):447-53. [PubMed 15677559 ] Vesanoid® data on file, Roche Pharmaceuticals. Topic 13099 Version 34.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.3 - C21.34 Licensed to: Morehouse School of Medicine | Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]